SUMMARY
Pentazocine and
Naloxone
Hydrochlorides
Tablets USP
Rx only
30158-4
Pentazocine and naloxone hydrochlorides tablets USP contain pentazocine hydrochloride USP, equivalent to 50 mg base, a member of the benzazocine series (also known as the benzomorphan series), and naloxone hydrochloride USP, equivalent to 0.5 mg base. Pentazocine and naloxone hydrochlorides tablets are an analgesic for oral administration.
|
| Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See DRUG ABUSE AND DEPENDENCE section.) | |
Pentazocine and naloxone hydrochlorides tablets are indicated for the relief of moderate to severe pain.
Pentazocine and naloxone hydrochlorides tablets are indicated for oral use only.
|
NEWS HIGHLIGHTSMedia Articles Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Opiate Painkillers May Encourage Spread Of Cancer
Source: Health News from Medical News Today [2009.11.23]
New research from the US adds weight to the growing body of evidence that opiate-based painkillers like morphine, which has been used to treat postoperative and chronic cancer pain for two hundred years, encourage cancer cells to grow and spread.
62-Year-Old Man Becomes First Patient In China Implanted With Rechargeable Neurostimulator For Chronic Pain
Source: Medical Devices / Diagnostics News From Medical News Today [2009.11.19]
St. Jude Medical, Inc. (NYSE:STJ) announced that a 62-year-old man from Shenzhen, Guangdong province has become the first patient in China to be implanted with the Eon™ neurostimulator, a rechargeable device used to help manage chronic pain. Despite prior back surgeries, the patient suffered from chronic back pain for more than a decade.
CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference In San Francisco
Source: Pain / Anesthetics News From Medical News Today [2009.11.19]
CNSBio Inc. will present recent Phase IIa proof-of-concept clinical trial data for CNSB015, an orally administered potassium channel modulator used in combination with opioids for the treatment of neuropathic pain, at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain on November 20-21, 2009 in San Francisco, CA. Dr.
Common Pain Relief Medication May Encourage Cancer Growth
Source: Pain / Anesthetics News From Medical News Today [2009.11.19]
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells. Two new studies advance that argument and demonstrate how shielding lung cancer cells from opiates reduces cell proliferation, invasion and migration in both cell-culture and mouse models.
Transplanting People's Own Stem Cells Into Heart Lessens Pain, Improves Ability To Walk
Source: Pain / Anesthetics News From Medical News Today [2009.11.19]
The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
Published Studies Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Hazards of pentazocine for neonatal analgesia: a single-centre experience over 10 years. [2008.09]
BACKGROUND: In developing countries, neonatal analgesia for surgical procedures is a major challenge where postoperative care is inadequate. AIM: To report experience of pentazocine for neonatal surgery in a Nigerian tertiary hospital... CONCLUSION: The use of pentazocine in neonates was associated with high morbidity and mortality. Caution is required when using pentazocine for neonatal analgesia where post-operative respiratory support is insufficient.
Improvement of memory impairment by (+)- and (-)-pentazocine via sigma, but not kappa opioid receptors. [2005.09.28]
(+/-)-Pentazocine is widely used clinically to treat mild to moderate pain as a racemic compound. Although it is known that (-)-pentazocine acts as a kappa opioid receptor agonist to exhibit analgesic actions and (+)-pentazocine acts as a sigma receptor agonist without analgesic effects, their combined effect on memory has not been investigated in detail.
Clinical Trials Related to Pentazocine and Naloxone (Pentazocine / Naloxone)
Effects of Pentazocine on Manic Symptoms [Active, not recruiting]
The opiate neurotransmitter system is thought to be involved in many abnormal mood states.
Some researchers have suggested that changes in this system may trigger the switch to/from
manic and depressive states in bipolar disorder. One problem with most of the currently
available opiate medications is that they can produce addiction/dependence. A particular
kind of opiate medication known as kappa-opiates may be able to produce changes in this
system with much less risk of addiction. This study looks at Talwin (a combination of
pentazocine and naloxone), a medication which affects the kappa and mu opiate systems. The
study will examine whether two doses of Talwin affect manic symptoms in people who have been
admitted to the hospital. This study will give more information about the involvement of the
opiate system in bipolar disorder, and give important information for use in developing new
treatments.
Effects of Pentazocine Versus Lorazepam or Placebo on Manic Symptoms [Recruiting]
Pilot data indicates that pentazocine decreases manic symptoms in hospitalized individuals.
To follow up these initial findings, we plan to conduct a larger, more rigorous,
double-blind study. We will examine whether pentazocine, an agent with kappa-opiate
activity, decreases manic symptoms.
|
